The biggest challenge in moving to value-based care is the mindset of providers accustomed to volume-based care, as they must work with payers to change the systems, said Susan Dentzer, president and CEO of The Network for Excellence in Health Innovation.
The biggest challenge in moving to value-based care is the mindset of providers accustomed to volume-based care, as they must work with payers to change the systems, said Susan Dentzer, president and CEO of The Network for Excellence in Health Innovation.
Transcript (slightly modified)
What are the biggest challenges still facing healthcare as it moves to value-based care?
Number one, inertia. Systems are so embedded in the volume model, many of them. They really cannot see a path forward in the value model. Particularly if it means doing lots of things differently. If it means a conceptual mind shift that, my hospital is better off empty rather than full. The physicians and the other people in the workforce who I once needed in certain numbers that I thought were predictable, now I don’t really know what my workforce should look like. And I need to innovate around my workforce, maybe I need fewer specialists, and I need more community health workers and peer counselors. Particularly at large academic centers, where you have people with appointments and a strong institutional basis that this is the way we run things, it’s very, very hard to change. So I think that first and foremost is probably the biggest obstacle.
And then, you can’t just want to do this change as a provider, you’ve got to have the payers who are willing to engage with you. So is there a meeting of minds between payers and providers to move to value together, and work out the kinks together, because as we hear over and over again, there are lots of kinks along the way.
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
Many Patients Stop GLP-1s Before Reaching Target Dose: Hamlet Gasoyan, PhD
June 19th 2025Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite provider follow-up and efforts to manage side effects, says Hamlet Gasoyan, PhD, Cleveland Clinic.
Read More